Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
← catalyst calendarNCT06117501 · readout ≤ 133 d
Sponsored by Axogen Corporation (industry) · AXGN — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-19 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Recurrent Cubital Tunnel Syndrome
- Recalcitrant Cubital Tunnel Syndrome
Intervention
- Device: Axoguard HA+ Nerve Protector™
Primary outcome
what the primary-completion date above is the date OFVisual analog scale (VAS)
measured 6-18 months
Permalink · AXGN's whole pipeline · Catalyst calendar · Every registered study · What changed